nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer.
Erika Paige HamiltonJavier CortesOzgur OzyilkanShin-Cheh ChenKatarina PetrakovaAleksey ManikhasGuy JerusalemRoberto HeggJens HuoberWei ZhangYanyun ChenMiguel MartinPublished in: Breast cancer research and treatment (2022)
The addition of tamoxifen to abemaciclib demonstrated greater OS benefit than monotherapy. This study confirmed the single-agent activity of abemaciclib in heavily pretreated women with endocrine-refractory HR + , HER2- MBC, as well as the previously reported primary PFS and ORR results, with no new safety signals observed. Trial Registration ClinicalTrials.gov Identifier: NCT02747004.